The government alleges McMillan personally used proceeds from a reimbursement stream in which he and companies he controlled received approximately $174 million, although the indictment does not assign an exact amount exclusively to his personal accounts.
WASHINGTON, DC — Federal prosecutors allege Michael McMillan and a group of wound-care businesses operating under the Protectus name received approximately $174 million after Medicare, TRICARE, and CHAMPVA paid claims involving costly skin-substitute products between 2019 and 2026.
The figure represents nearly two-thirds of approximately $268 million that government healthcare programs allegedly paid on challenged claims, making the Protectus collections central to a federal case involving healthcare-fraud conspiracy, kickback accusations, transactional money-laundering counts, seizure, and forfeiture demands.
McMillan remains presumed innocent; no court has determined that the $174 million was criminal revenue, and prosecutors must prove through admissible evidence that the challenged payments resulted from intentional fraud or unlawful remuneration rather than legitimate wound-care commerce.
The federal filing says McMillan owned and controlled Protectus LLC and related entities, but it describes the $174 million as money received collectively by “McMillan and Protectus,” without publicly identifying an exact amount deposited solely into McMillan’s personal bank accounts.
That distinction is essential because corporate gross receipts, personal income, alleged criminal proceeds, government-program loss, provider compensation, seized assets, and forfeitable property are separate financial categories whose values may differ substantially throughout litigation and any eventual sentencing proceeding.
The Indictment’s $174 Million Allegation
According to the federal indictment outlining the Michael McMillan allegations, government programs paid approximately $268 million on skin-substitute claims, medical providers allegedly retained about $94 million, and McMillan together with Protectus received the remaining approximately $174 million.
The arithmetic creates a simple prosecutorial narrative: the alleged provider share and the alleged Protectus share together account for the full reimbursement total, while also showing how authorities believe each successful claim financed both sides of the challenged arrangement.
Prosecutors characterize the providers’ approximately $94 million as illegal kickbacks disguised as rebates, discounts, or profits, while portraying the approximately $174 million flowing toward McMillan and Protectus as proceeds generated through fraudulent billing and corrupted purchasing decisions.
The defense can dispute every component of that interpretation, including whether providers received unlawful remuneration, whether submitted acquisition prices were false, whether claims were medically payable, and whether Protectus collections constitute criminal proceeds rather than revenue from products actually supplied.
What “McMillan and Protectus” Means
The charging document’s combined phrasing does not reveal how prosecutors allocated the $174 million among McMillan, six related companies, operating accounts, vendors, manufacturers, employees, taxes, refunds, representatives, loans, distributions, or other expenses incurred during nearly seven years.
Reporting that McMillan personally pocketed the entire amount would therefore exceed the public allegation, even though prosecutors separately claim that he controlled the companies and used illegal proceeds to finance what they describe as an exceptionally lavish personal lifestyle.
Ownership and control can help prosecutors connect an executive with corporate decisions, bank accounts, compensation, and distributions, but those relationships do not eliminate the government’s obligation to establish knowledge, intent, source, and personal participation for each charged offense.
Corporate records may eventually show how much McMillan received through salary, draws, distributions, loans, expense reimbursements, property payments, or transfers, while the defense may identify legitimate revenue and documented business obligations within the same financial stream.
Six Companies Form the Protectus Group
The indictment collectively defines Protectus as six Nevada limited liability companies named Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC, each allegedly owned and controlled by McMillan.
Those entities appear within the factual allegations rather than as separately charged corporate defendants, while McMillan alone is named as the defendant facing two conspiracy counts and seven counts involving monetary transactions in allegedly criminally derived property.
Prosecutors may use common ownership, shared personnel, coordinated invoices, centralized billing support, linked bank accounts, and intercompany transfers to argue that the entities functioned as an integrated operation directed by McMillan throughout the relevant period.
The defense may answer that related companies performed distinct lawful functions, maintained separate books, paid genuine operating expenses, followed professional guidance, and cannot be collapsed into a single criminal enterprise merely because one owner exercised ultimate managerial authority.
How the Alleged Reimbursement Split Worked
Prosecutors say Protectus offered physicians, podiatrists, nurse practitioners, and other medical providers skin-substitute products without requiring upfront payment, allowing practices to treat patients and await the government program’s claim decision before paying for the supplied material.
If Medicare, TRICARE, or CHAMPVA denied reimbursement, the provider allegedly owed nothing for the associated product, but a successful claim allegedly produced a Protectus invoice equaling approximately 60 percent to 70 percent of the government payment.
That formula allegedly left the treating practice with approximately 30 percent to 40 percent, sometimes representing thousands of dollars for a single application, while directing the larger share toward McMillan’s companies after the federal reimbursement arrived.
Authorities contend the provider margin was not an ordinary commercial discount, because its connection to successful government payment allegedly guaranteed profit, eliminated denial risk, influenced product selection, and rewarded purchases ultimately financed through federally supported healthcare programs.
McMillan may contend that the arrangements reflected lawful credit terms, collection risk, discounts, product pricing, and genuine treatment value, requiring prosecutors to prove that remuneration was knowingly and willfully offered to induce federally reimbursable business.
Why the $174 Million Is Not Automatically Profit
Gross corporate receipts do not equal personal profit, because a distributor receiving $174 million may also pay manufacturers, sales commissions, salaries, taxes, rent, insurance, technology expenses, professional fees, refunds, financing costs, and other legitimate or disputed obligations.
The indictment alleges approximately $27 million went to sales representatives through compensation tied to reimbursements generated by recruited providers, meaning that commission figure appears within the broader Protectus receipt stream rather than adding new government losses beyond $268 million.
Prosecutors nevertheless may argue that ordinary expenses paid with fraud proceeds do not transform the underlying receipts into lawful money, while the defense may contend that product value and genuine costs materially reduce any defensible loss, restitution, or forfeiture calculation.
Any final financial judgment could therefore differ significantly from the indictment’s headline totals after claim-level review, tracing disputes, medical-value arguments, refunds, credits, third-party interests, and judicial decisions about how governing statutes measure proceeds and loss.
How McMillan Allegedly Benefited Personally
The indictment says McMillan used alleged scheme proceeds to fund a lavish lifestyle, and its seven monetary-transaction counts identify payments connected with four real-estate properties, a Lamborghini, a Cadillac Escalade, and a Cessna Citation private aircraft.
Together, those seven listed transactions total about $6.28 million, a substantial amount that prosecutors will likely present as evidence of personal benefit, financial control, and knowledge of the source of money moving through the identified accounts.
However, the transaction total remains far below $174 million, and the listed payments do not establish how much McMillan personally received overall, because corporate revenue can be spent, transferred, reinvested, distributed, or retained through numerous lawful and allegedly unlawful pathways.
Each financial count requires transaction-specific proof that McMillan knowingly conducted or attempted a monetary transaction exceeding $10,000 with property derived from specified unlawful activity, rather than permitting conviction merely because he purchased expensive assets during rapid business growth.
Real Estate, Vehicles, and an Aircraft
The charged transfers allegedly include payments associated with a Dallas condominium, residences in Las Vegas, Simpsonville, Kentucky, and Del Mar, California, two luxury vehicles, and a 1997 Cessna Citation VII acquired through an account tied to another company.
Account records, closing statements, title files, dealer invoices, aircraft escrow documents, tax returns, loan agreements, and internal ledgers may show whether Protectus-related funds reached those purchases and may also reveal any legitimate deposits or financing sources.
The defense can challenge whether funds were commingled, whether prosecutors applied an accepted tracing method, whether a corporate payment represented compensation or a documented business transaction, and whether McMillan knew that any transferred money allegedly came from unlawful activity.
Luxury property can make a complicated billing prosecution visually compelling, but prestige and price cannot substitute for proof, since neither a private aircraft nor an expensive residence becomes criminal property simply because its purchaser operated a successful healthcare company.
The Government’s False-Billing Theory
The indictment alleges participating practices submitted materially false acquisition-price information by failing to disclose discounts, rebates, refunds, denial protections, and other adjustments affecting what providers actually expected to pay for the skin-substitute products supplied by Protectus.
Prosecutors specifically describe information placed in Box 19 of certain Medicare claims, arguing that the stated figure did not reflect the provider’s genuine economic obligation after the reimbursement-based invoice formula and no-charge-after-denial policy were considered together.
The government also alleges Protectus employees helped practices prepare claims or supplied pricing information, potentially linking McMillan’s business operations to representations submitted under provider identifiers to federal programs responsible for determining eligibility and reimbursement amounts.
Defense arguments may address who completed and certified individual claims, what pricing guidance applied at the time, whether provider interpretations were reasonable, whether information was material, and whether any error reflected deliberate deception rather than administrative complexity.
The Kickback Theory Behind the Money
Federal authorities allege McMillan and Protectus paid approximately $94 million in provider kickbacks through the retained reimbursement shares, creating a financial incentive for practices to order and apply products whose cost would ultimately be borne by government healthcare programs.
They also allege representatives received about $27 million in improper commissions tied to providers they recruited, reinforcing the government’s claim that reimbursement volume and successful collections drove compensation throughout the sales network surrounding Protectus products.
Percentage compensation is not automatically criminal, but prosecutors can pursue arrangements when they prove remuneration was knowingly and willfully offered or paid for referrals, recommendations, purchases, or orders involving items reimbursable under a federal healthcare program.
McMillan can test whether written agreements, compliance advice, fair-market pricing, provider independence, bona fide services, established commercial practices, or statutory protections support a lawful explanation, although falling outside a regulatory safe harbor does not alone prove criminal intent.
Medicare, TRICARE, and CHAMPVA Payments
The alleged reimbursement pool included Medicare payments serving older adults and qualifying people with disabilities, TRICARE coverage supporting military communities, and CHAMPVA benefits available to eligible spouses, children, survivors, and caregivers connected with veterans.
Because the programs operate through different statutory and administrative systems, investigators can compare claims, remittances, provider certifications, payment rules, and beneficiary records across payers to determine whether the same Protectus business model produced recurring disputed representations.
Skin substitutes can deliver legitimate clinical value for appropriately selected chronic wounds, so the criminal case does not turn on declaring every product ineffective, but on alleged kickbacks, price reporting, intent, causation, and federal payment eligibility.
Patients may have received real treatment while claims remained legally disputed, just as a successful reimbursement does not establish that every clinical decision, financial arrangement, invoice, discount, or claim entry satisfied the governing program requirements.
Following $268 Million Through the System
Investigators can align program payments with practice deposits, Protectus invoices, provider checks, company receipts, sales commissions, intercompany transfers, owner distributions, and asset purchases, producing chronological maps showing how each dollar allegedly moved after claim adjudication.
They may compare standardized percentages across practices, test whether denied claims produced no invoice, review communications promoting provider profit, and determine whether company staff monitored reimbursement closely enough to calculate invoices and commissions after government payments.
Banking evidence can identify authorized signers, transfer memos, account balances, counterparties, and payment destinations, while corporate accounting can link those entries to product acquisitions, payroll, taxes, financing, refunds, and potentially legitimate revenue unrelated to the challenged claims.
The most persuasive case will require records that converge upon a consistent financial route, because a headline total cannot independently demonstrate what McMillan knew, which claims were tainted, or how much allegedly unlawful money entered each personal transaction.
Why Corporate Control Matters
Prosecutors will likely emphasize McMillan’s alleged ownership and control to show he could set pricing policies, approve compensation, direct employees, access accounts, receive reports, and authorize transfers across companies participating in the challenged reimbursement model.
Emails, messages, spreadsheets, bank authorizations, contracts, commission reports, tax documents, and employee testimony could establish his involvement, while defense evidence could show delegated responsibilities, professional reliance, incomplete information, or actions inconsistent with an intentional conspiracy.
Executive status alone cannot establish guilt, because federal prosecutors must connect McMillan personally to the alleged agreement and required criminal purpose rather than impose automatic liability for every mistake or disputed transaction in businesses he owned.
Conversely, operating through limited liability companies does not immunize an owner who knowingly directs illegal conduct, meaning the factual question will concern what McMillan authorized, understood, received, and intended throughout the alleged operation.
Seized Assets Are a Separate Number
Federal officials reported approximately $35 million in assets seized as part of the McMillan matter, including cash, luxury vehicles, and other property, but seizure preserves disputed assets and does not establish guilt, ownership, criminal origin, or permanent forfeiture.
That $35 million figure should remain separate from the approximately $174 million received by McMillan and Protectus, the approximately $268 million paid by government programs, the approximately $94 million provider share, and the seven charged transactions totaling roughly $6.28 million.
McMillan and qualifying third parties may challenge tracing, valuation, liens, financing, ownership, commingling, and substitute-asset requests, while prosecutors must satisfy applicable burdens before restrained property can become permanently forfeited following a qualifying conviction.
Market changes, outstanding debts, preservation costs, depreciation, competing interests, and court rulings may substantially alter the value ultimately recovered, demonstrating why an announcement-day seizure estimate cannot be treated as final restitution or proven criminal proceeds.
A Central Case in the 2026 Takedown
The Justice Department announced McMillan’s indictment during its 2026 National Health Care Fraud Takedown, which brought charges against 455 defendants across 56 federal districts in alleged schemes collectively involving more than $6.5 billion in false healthcare claims.
Northern District of Texas authorities described seven cases involving thirteen defendants and more than $365 million in alleged fraudulent billing, making the McMillan matter the district’s largest announced case according to the approximately $268 million program-payment figure.
An NBC 5 Dallas-Fort Worth report about the North Texas enforcement action highlighted the seized houses, private jet, and luxury vehicles while explaining that the wider operation targeted alleged fraud affecting elderly beneficiaries, military families, and other vulnerable patients.
Federal officials credited investigators from the Federal Bureau of Investigation, the Health and Human Services inspector general, the Defense Criminal Investigative Service, and the Department of Veterans Affairs inspector general with developing evidence supporting the prosecution of McMillan.
What the Nine Counts Allege
Count One charges conspiracy to commit healthcare fraud, alleging an agreement to obtain government money through materially false claims and kickback-induced billing, while Count Two charges a conspiracy involving federal-program kickbacks and interference with lawful government functions.
Counts Three through Nine concern monetary transactions in criminally derived property, each identifying a payment greater than $10,000 allegedly connected with proceeds from the two predicate conspiracies and associated with a particular residence, vehicle, or aircraft.
The indictment does not charge hundreds of millions of dollars as individual substantive claim counts, meaning prosecutors may use representative transactions, aggregate data, witnesses, and financial records to prove the scope and operation of the alleged conspiracies.
McMillan can challenge agreement, knowledge, materiality, causation, pricing interpretations, provider conduct, witness incentives, tracing methods, search procedures, expert analysis, forfeiture claims, and whether selected examples fairly characterize many years of varied commercial relationships.
Compliance Lessons from the Protectus Allegations
Medical suppliers should document fixed or objectively supported prices, every rebate and refund, denial-risk allocations, product credits, billing assistance, representative compensation, and provider communications whenever federally reimbursed products generate unusually large margins or contingent payments.
Medical practices should independently verify acquisition-price disclosures, preserve clinical and financial records, evaluate medical necessity, and reject arrangements that promise guaranteed profit or eliminate all downside while dividing government reimbursement according to a predetermined percentage.
Executives should require source-of-funds reviews before major personal purchases when company revenue depends heavily on government claims, particularly where accounts include disputed reimbursements, contingent invoices, affiliate transfers, unresolved refunds, or compensation linked to claim volume.
Boards and compliance officers should trace sample transactions from manufacturer purchase through shipment, application, claim submission, payer decision, provider collection, supplier invoice, commission payment, corporate deposit, owner distribution, and any later acquisition of valuable personal property.
Lawful Reputation Management During Federal Scrutiny
Amicus International Consulting publishes reporting and analysis concerning lawful due diligence, cross-border risk, identity integrity, and reputational exposure while distinguishing legitimate planning from concealment intended to obstruct investigators, courts, creditors, regulators, or mandatory reporting duties.
Its crisis public-relations guidance emphasizes accurate timelines, evidence preservation, disciplined public statements, and coordination with qualified counsel, principles especially important when headline financial totals risk being repeated without their procedural context or underlying accounting distinctions.
Organizations facing allegations should suspend routine deletion, preserve claims and banking records, identify authorized spokespeople, correct material misinformation carefully, and avoid transferring assets or contacting witnesses in ways that could create additional obstruction, retaliation, or forfeiture concerns.
No communications campaign can erase an authentic indictment or replace a legal defense, but precise terminology can preserve the crucial differences among allegations, corporate receipts, personal income, seized assets, adjudicated loss, restitution, and permanent forfeiture.
What Prosecutors Must Prove About the Money
To convict McMillan, prosecutors must prove his knowing participation in the charged conspiracies and establish required intent through admissible evidence, rather than relying solely upon company ownership, rapid growth, reimbursement size, valuable purchases, or the emotional force of public-program losses.
They must show how allegedly false pricing or illegal remuneration caused government payments, then connect qualifying proceeds with the seven charged monetary transactions while proving McMillan possessed the knowledge required for each transfer at the relevant time.
Aggregate data can demonstrate scale and identify patterns, but the defense can demand claim-level distinctions involving medical necessity, product delivery, acquisition costs, refunds, provider independence, billing responsibility, program guidance, and legitimate commercial revenue throughout the relevant years.
Witnesses may include providers, sales representatives, billers, accountants, employees, vendors, and investigators, whose credibility will depend upon documents, incentives, immunity arrangements, personal exposure, consistency, and whether complete communications support or contradict their recollections.
What Happens Next
The McMillan prosecution will proceed through discovery, pretrial motions, expert analysis, asset litigation, and possible negotiations, potentially requiring extensive review of nearly seven years of claims, invoices, clinical records, company books, bank statements, messages, and contracts.
Future filings may clarify how the $174 million moved among Protectus entities, how much McMillan allegedly received personally, whether legitimate costs reduce proposed loss, and which assets prosecutors believe can be traced directly to specified unlawful activity.
Until those records are tested, the most accurate account remains that prosecutors allege McMillan and Protectus collectively received approximately $174 million, while also accusing McMillan of personally using an unspecified portion of illegal proceeds to acquire valuable assets.
Michael McMillan remains presumed innocent; every healthcare-fraud, kickback, monetary-transaction, seizure, and forfeiture allegation remains unresolved, and criminal responsibility can arise only through a valid guilty plea or proof beyond a reasonable doubt in federal court.
For more coverage on this topic, see related articles on our publishing site.
